FULL DOSE CHOP CHEMOTHERAPY IN ELDERLY PATIENTS WITH NON-HODGKINS-LYMPHOMA

被引:29
作者
EPELBAUM, R
HAIM, N
LEVIOV, M
BENSHAHAR, M
BENARIE, Y
DROR, Y
FARAGGI, D
机构
[1] RAMBAM MED CTR,DEPT PATHOL,HAIFA,ISRAEL
[2] TECHNION ISRAEL INST TECHNOL,FAC MED,HAIFA,ISRAEL
[3] UNIV HAIFA,INST TECHNOL,IL-31999 HAIFA,ISRAEL
[4] UNIV HAIFA,DEPT STAT,IL-31999 HAIFA,ISRAEL
关键词
D O I
10.3109/02841869509093644
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Twenty-eight previously untreated elderly patients (median age 73 years, range 65-88) with aggressive non-Hodgkin's lymphoma were treated with full-dose CHOP chemotherapy between 1989 and 1992. The median of the average relative dose intensity (ARDI) was calculated for the initial cycles needed to achieve a maximal response or to determine progression of disease (1-6 cycles, median 4), as well as for the whole treatment course, For patients aged 65-74, both ARDIs were 0.89. A comparable group of 36 elderly patients who received reduced doses of CHOP from the start, served as a historical control. These was an increase of 11% and 29% in the ARDIs of the full-dose CHOP as compared with the reduced CHOP, in the initial cycles and for the whole treatment course respectively. Grade III-IV leukopenia was the main toxicity observed in 57% of the patients, and 7 patients were hospitalized for fever and leukopenia. There was no treatment-related death, It is concluded that CHOP chemotherapy without initial dose reduction is feasible in patients aged 65-74 years, resulting in high actual dose intensity with a reasonable degree of toxicity.
引用
收藏
页码:87 / 91
页数:5
相关论文
共 35 条
[1]  
[Anonymous], 1982, CANCER, V49, P2112
[2]   A PHASE-II TRIAL OF A CHEMOTHERAPY COMBINATION IN ELDERLY PATIENTS WITH AGGRESSIVE LYMPHOMA [J].
ANSELL, SM ;
FALKSON, G .
ANNALS OF ONCOLOGY, 1993, 4 (02) :172-172
[3]   AGGRESSIVE CHEMOTHERAPY FOR DIFFUSE HISTIOCYTIC LYMPHOMA IN THE ELDERLY - INCREASED COMPLICATIONS WITH ADVANCING AGE [J].
ARMITAGE, JO ;
POTTER, JF .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 1984, 32 (04) :269-273
[4]  
Balducci L, 1992, Oncology (Williston Park), V6, P62
[5]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[6]  
COFFER B, 1990, 4TH P INT C MAL LYMP
[7]  
COOPER IA, 1991, P AN M AM SOC CLIN, V10, P271
[8]   EFFECT OF AGE ON THERAPEUTIC OUTCOME IN ADVANCED DIFFUSE HISTIOCYTIC LYMPHOMA - THE SOUTHWEST-ONCOLOGY-GROUP EXPERIENCE [J].
DIXON, DO ;
NEILAN, B ;
JONES, SE ;
LIPSCHITZ, DA ;
MILLER, TP ;
GROZEA, PN ;
WILSON, HE .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (03) :295-305
[9]  
EPELBAUM R, 1990, CANCER-AM CANCER SOC, V66, P1124, DOI 10.1002/1097-0142(19900915)66:6<1124::AID-CNCR2820660608>3.0.CO
[10]  
2-T